Press release
Pertussis Market to Set Phenomenal Growth From 2025 to 2034
Pertussis Market
Pertussis, commonly known as whooping cough, is a highly contagious respiratory infection caused by Bordetella pertussis. Despite widespread vaccination, pertussis continues to pose a significant public health burden due to waning immunity and outbreaks in both developed and developing countries.
The Pertussis Market is gaining momentum as global health authorities intensify immunization programs, booster schedules, and awareness campaigns. With the advent of combination vaccines and innovations in vaccine delivery, the market is poised for steady growth between 2024 and 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71464
Market Overview
• Market Size 2024: Valued at USD 8.6 billion
• Forecast 2034: Expected to reach USD 14.1 billion
• CAGR (2024-2034): ~5.1%
Key Highlights
• Rising adoption of DTaP and Tdap vaccines across pediatric and adult populations.
• Booster programs expanding in the U.S., Europe, and parts of Asia-Pacific.
• Partnerships between global health agencies (WHO, UNICEF) and vaccine manufacturers improving distribution in low-income countries.
• Strong pipeline for next-generation pertussis vaccines with longer-lasting immunity.
Segmentation Analysis
By Vaccine Type
• Whole-cell Pertussis Vaccines (wP)
• Acellular Pertussis Vaccines (aP)
• Combination Vaccines (DTaP, Tdap, DTP-HepB-Hib, etc.)
By Age Group
• Infants & Children
• Adolescents
• Adults
By Distribution Channel
• Public Health Programs (government & NGO initiatives)
• Private Vaccination Clinics
• Hospital Pharmacies
• Retail & Online Pharmacies
By End User
• Hospitals
• Pediatric Clinics
• Ambulatory Care Centers
• Public Health Agencies
Summary:
Combination vaccines dominate the market, particularly DTaP and Tdap formulations, due to convenience and high compliance rates. While infants remain the largest vaccination group, adolescent and adult booster programs are increasingly critical to reducing transmission.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71464/pertussis-market
Regional Analysis
North America
• Strongest market share in 2024, led by the U.S.
• High coverage of childhood vaccination and mandatory school-entry immunization policies.
• Growth supported by Tdap boosters for adolescents, adults, and pregnant women.
Europe
• Widespread adoption of acellular pertussis vaccines across Western Europe.
• Regular booster schedules for adolescents and adults sustain market growth.
• Focus on catch-up immunization programs in Eastern Europe.
Asia-Pacific
• Fastest-growing region with CAGR ~6.2%.
• Large infant population in China, India, and Southeast Asia driving demand.
• National immunization programs expanding coverage, supported by WHO and UNICEF partnerships.
Latin America
• Brazil and Mexico lead adoption with publicly funded vaccination programs.
• Market growth hindered by vaccine shortages in rural areas.
Middle East & Africa
• Smaller market share but improving access due to global vaccine alliances (e.g., Gavi).
• GCC nations focusing on expanding routine childhood immunization.
Summary:
North America and Europe dominate in terms of booster program penetration, but Asia-Pacific will emerge as the growth engine due to its large pediatric base and expanding government-led vaccination drives.
Market Dynamics
Key Growth Drivers
• Increasing global focus on childhood immunization programs.
• Rising demand for booster vaccines in adolescents and adults.
• Technological advancements in acellular and combination vaccines.
• International collaborations ensuring vaccine access in low-income nations.
Key Challenges
• Waning immunity leading to resurgence of pertussis outbreaks.
• Limited healthcare access and infrastructure in low-income regions.
• Vaccine hesitancy and misinformation in certain geographies.
Latest Trends
• Growth of DTaP-based combination vaccines that reduce the number of injections.
• Research into longer-lasting pertussis vaccines to reduce booster frequency.
• Increasing adoption of maternal immunization programs to protect newborns.
• Expansion of public-private partnerships for affordable vaccine distribution.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71464
Competitor Analysis
Major Players
• Sanofi Pasteur - Daptacel, Adacel
• GlaxoSmithKline plc (GSK) - Infanrix, Boostrix
• Mitsubishi Tanabe Pharma - Pertussis vaccine portfolio in Asia
• Serum Institute of India - DTP and combination vaccines
• Bharat Biotech - Pertussis-containing vaccine formulations
• Biological E Limited - Pentavalent vaccines
• Walvax Biotechnology - Expanding pertussis vaccine capacity in China
• China National Biotec Group (CNBG) - Large-scale pertussis vaccine supply
• PT Bio Farma - Key supplier in Southeast Asia
• Emergent BioSolutions - Partnerships for booster immunization
Competitive Summary:
The market is dominated by Sanofi and GSK, with strong global sales of their DTaP and Tdap products. However, emerging Asian players such as Serum Institute of India, Bharat Biotech, and Walvax Biotechnology are scaling up production, especially for developing regions.
Conclusion
The Pertussis Market is projected to grow from USD 8.6 billion in 2024 to USD 14.1 billion by 2034, at a CAGR of 5.1%. Rising global immunization initiatives, stronger booster programs, and innovations in combination vaccines are the core growth drivers.
While vaccine hesitancy and waning immunity remain challenges, the global push for universal immunization ensures a robust long-term outlook. Emerging markets in Asia-Pacific and Latin America will see the fastest growth, supported by government and NGO-driven programs.
Key Takeaway: Companies investing in affordable, long-lasting combination vaccines and booster programs are best positioned to capture market opportunities over the next decade.
This report is also available in the following languages : Japanese (百日咳市場), Korean (백일해 시장), Chinese (百日咳市场), French (Marché de la coqueluche), German (Keuchhustenmarkt), and Italian (Mercato della pertosse), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71464
Our More Reports:
Inferior Vena Cava Filter Market
https://exactitudeconsultancy.com/reports/71516/inferior-vena-cava-filter-market
Pneumothorax Treatment Device Market
https://exactitudeconsultancy.com/reports/71518/pneumothorax-treatment-device-market
Idiopathic Pulmonary Fibrosis Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71520/idiopathic-pulmonary-fibrosis-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pertussis Market to Set Phenomenal Growth From 2025 to 2034 here
News-ID: 4167963 • Views: …
More Releases from Exactitude Consultancy
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction
Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases.
As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies…
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,…
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing…
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction
Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy.
As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation…
More Releases for Pertussis
Diphtheria, Pertussis, and Tetanus Vaccine Market
According to a new report published by Allied Market Research, titled, "Diphtheria, Pertussis, and Tetanus Vaccine Market by Product Type [DTaP (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel), Td (Decavac and Tenivac), and Tdap (Boostrix and Adacel)], Vaccine Type (Whole-Cell Vaccine and Acellular Vaccine), Age Group (Adult and Pediatric), and End User (Hospitals, Clinics, and Vaccination Centers) - Global Opportunity and Forecast, 2019-2026 ".
The Global market size of Diphtheria, Pertussis,…
Growth in Adoption of Pertussis Vaccination and Government Insurance are Project …
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
Global Pertussis Vaccine Consumption 2016 Market Research Report
The Global Pertussis Vaccine Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Pertussis Vaccine market.
First, the report provides a basic overview of the Pertussis Vaccine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.
Secondly, the report states the global Pertussis Vaccine market size (volume and value),…
Pertussis Vaccine Market: Estimated to Flourish by 2016 - 2024
The Pertussis Vaccine Market report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.
Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S,…
Pertussis Vaccine Industry 2024 Market Research Report
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
Pertussis Vaccine Industry 2024 Market Research Report
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free…
